{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:48:52Z","timestamp":1793407732822,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007231","name":"Cancerf\u00f6reningen i Stockholm","doi-asserted-by":"publisher","award":["111293"],"award-info":[{"award-number":["111293"]}],"id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["733006"],"award-info":[{"award-number":["733006"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["779293"],"award-info":[{"award-number":["779293"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["GSC203"],"award-info":[{"award-number":["GSC203"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015676","name":"Berlin-Brandenburger Centrum f\u00fcr Regenerative Therapien","doi-asserted-by":"publisher","award":["01EC1402B"],"award-info":[{"award-number":["01EC1402B"]}],"id":[{"id":"10.13039\/501100015676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015676","name":"Berlin-Brandenburger Centrum f\u00fcr Regenerative Therapien","doi-asserted-by":"publisher","award":["FOR2165"],"award-info":[{"award-number":["FOR2165"]}],"id":[{"id":"10.13039\/501100015676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015676","name":"Berlin-Brandenburger Centrum f\u00fcr Regenerative Therapien","doi-asserted-by":"publisher","award":["GE2512\/2-2"],"award-info":[{"award-number":["GE2512\/2-2"]}],"id":[{"id":"10.13039\/501100015676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2013\/671"],"award-info":[{"award-number":["CAN2013\/671"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["K2014-64X-05971-34-4"],"award-info":[{"award-number":["K2014-64X-05971-34-4"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.molmed.2018.12.006","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T18:39:54Z","timestamp":1548873594000},"page":"149-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":367,"title":["Intravascular Mesenchymal Stromal\/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-5957","authenticated-orcid":false,"given":"Guido","family":"Moll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Ankrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Kamhieh-Milz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bieback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Ringd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2018.12.006_bib0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2018.12.006_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","article-title":"MSC-based product characterization for clinical trials: an FDA perspective","volume":"14","author":"Mendicino","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2018.12.006_bib0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmed.2010.02.005","article-title":"Mesenchymal stem cell therapy: two steps forward, one step back","volume":"16","author":"Ankrum","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nm.3028","article-title":"The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine","volume":"19","author":"Bianco","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0030","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/stem.1452","article-title":"Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?","volume":"31","author":"Griffin","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0035","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/stem.1111","article-title":"Are therapeutic human mesenchymal stromal cells compatible with human blood?","volume":"30","author":"Moll","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2018.12.006_bib0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMp1613723","article-title":"Clarifying stem-cell therapy\u2019s benefits and risks","volume":"376","author":"Marks","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/468485a","article-title":"Korean deaths spark inquiry","volume":"468","author":"Cyranoski","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2018.12.006_bib0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3349\/ymj.2013.54.5.1293","article-title":"Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy","volume":"54","author":"Jung","year":"2013","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.molmed.2018.12.006_bib0060","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.transproceed.2017.03.078","article-title":"Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: a report of two cases and literature review","volume":"49","author":"Wu","year":"2017","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.molmed.2018.12.006_bib0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/sctm.18-0015","article-title":"Clinical cellular therapeutics accelerate clot formation","volume":"7","author":"George","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(04)15695-X","article-title":"Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs","volume":"363","author":"Vulliet","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2018.12.006_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mvr.2009.02.001","article-title":"Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy","volume":"77","author":"Furlani","year":"2009","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.molmed.2018.12.006_bib0080","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/CIRCRESAHA.108.187724","article-title":"Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics","volume":"104","author":"Toma","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2018.12.006_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042819","article-title":"Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity","volume":"7","author":"Stephenne","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2018.12.006_bib0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2012.12.134","article-title":"Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism","volume":"431","author":"Tatsumi","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2018.12.006_bib0095","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/stem.2050","article-title":"Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: amelioration by antithrombin therapy","volume":"33","author":"Gleeson","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0100","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1089\/scd.2015.0120","article-title":"Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua","volume":"24","author":"Moll","year":"2015","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.molmed.2018.12.006_bib0105","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/hepr.12507","article-title":"Enhanced survival of mice infused with bone marrow-derived as compared with adipose-derived mesenchymal stem cells","volume":"45","author":"Shiratsuki","year":"2015","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.molmed.2018.12.006_bib0110","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/TA.0000000000001485","article-title":"Procoagulant activity of human mesenchymal stem cells","volume":"83","author":"Christy","year":"2017","journal-title":"J. Trauma Acute Care Surg."},{"key":"10.1016\/j.molmed.2018.12.006_bib0115","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.21906","article-title":"Selection of tissue factor-deficient cell transplants as a novel strategy for improving hemocompatibility of human bone marrow stromal cells","volume":"8","author":"Oeller","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.molmed.2018.12.006_bib0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7150\/thno.16911","article-title":"Heparin improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy","volume":"7","author":"Liao","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.molmed.2018.12.006_bib0125","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/stem.2891","article-title":"Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial","volume":"36","author":"Perlee","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.molmed.2018.12.006_bib0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.molmed.2018.12.006_bib0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","article-title":"Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo","volume":"17","author":"Friedenstein","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.molmed.2018.12.006_bib0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.molmed.2018.12.006_bib0150","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation","volume":"30","author":"von Bahr","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0160","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2018.12.006_bib0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","article-title":"A perivascular origin for mesenchymal stem cells in multiple human organs","volume":"3","author":"Crisan","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2018.12.006_bib0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2008.03.002","article-title":"Mesenchymal stem cells: revisiting history, concepts, and assays","volume":"2","author":"Bianco","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2018.12.006_bib0175","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1634\/stemcells.2007-0023","article-title":"Functional network analysis of the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow","volume":"25","author":"Tsai","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0180","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1634\/stemcells.2007-0594","article-title":"Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells","volume":"26","author":"Parolini","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.placenta.2014.12.014","article-title":"Mesenchymal stem cells reside in a vascular niche in the decidua basalis and are absent in remodelled spiral arterioles","volume":"36","author":"Kusuma","year":"2015","journal-title":"Placenta"},{"key":"10.1016\/j.molmed.2018.12.006_bib0190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41586-018-0698-6","article-title":"Single-cell reconstruction of the early maternal-fetal interface in humans","volume":"563","author":"Vento-Tormo","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2018.12.006_bib0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/sctm.17-0167","article-title":"Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease","volume":"7","author":"Ringden","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0200","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/stem.1729","article-title":"Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?","volume":"32","author":"Moll","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tcm.2015.12.001","article-title":"Tissue factor as a link between inflammation and coagulation","volume":"26","author":"Witkowski","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0210","first-page":"1087","article-title":"Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis","volume":"134","author":"Drake","year":"1989","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V76.1.86.86","article-title":"Tissue factor: identification and characterization of cell types in human placentae","volume":"76","author":"Faulk","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2018.12.006_bib0220","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(02)12020-4","article-title":"Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation","volume":"360","author":"Moberg","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2018.12.006_bib0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0230","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diabetes.50.4.710","article-title":"Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol","volume":"50","author":"Ryan","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2018.12.006_bib0235","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/TP.0b013e3181c478fd","article-title":"Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success","volume":"89","author":"Koh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.molmed.2018.12.006_bib0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.it.2009.09.005","article-title":"Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?","volume":"31","author":"Nilsson","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","article-title":"Mesenchymal stem cell homing: the devil is in the details","volume":"4","author":"Karp","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2018.12.006_bib0250","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1634\/stemcells.2007-0140","article-title":"Circulating connective tissue precursors: extreme rarity in humans and chondrogenic potential in guinea pigs","volume":"25","author":"Kuznetsov","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1634\/stemcells.2006-0335","article-title":"Concise review: multipotent mesenchymal stromal cells in blood","volume":"25","author":"He","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0260","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/kem206","article-title":"Human bone marrow mesenchymal stem cells in vivo","volume":"47","author":"Jones","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.molmed.2018.12.006_bib0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-18603-0_1","article-title":"Thromboinflammation in therapeutic medicine","volume":"865","author":"Ekdahl","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0270","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2337\/diabetes.48.10.1907","article-title":"Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?","volume":"48","author":"Bennet","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2018.12.006_bib0275","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2002-06-1830","article-title":"Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates","volume":"101","author":"Devine","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2018.12.006_bib0280","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/scd.2008.0253","article-title":"Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect","volume":"18","author":"Fischer","year":"2009","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.molmed.2018.12.006_bib0285","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.molmed.2018.12.006_bib0290","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09262","article-title":"Mesenchymal and haematopoietic stem cells form a unique bone marrow niche","volume":"466","author":"Mendez-Ferrer","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2018.12.006_bib0295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.stem.2008.10.017","article-title":"Differential mobilization of subsets of progenitor cells from the bone marrow","volume":"4","author":"Pitchford","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmed.2018.12.006_bib0300","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s12015-010-9212-8","article-title":"The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes","volume":"7","author":"Marquez-Curtis","year":"2011","journal-title":"Stem Cell Rev."},{"key":"10.1016\/j.molmed.2018.12.006_bib0305","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.4049\/jimmunol.0803055","article-title":"C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1\/2 phosphorylation","volume":"182","author":"Schraufstatter","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021703","article-title":"Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses","volume":"6","author":"Moll","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2018.12.006_bib0315","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nature06685","article-title":"Haematopoietic stem cell release is regulated by circadian oscillations","volume":"452","author":"Mendez-Ferrer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2018.12.006_bib0320","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/ATVBAHA.107.160317","article-title":"Circulating endothelial progenitor cells exhibit diurnal variation","volume":"28","author":"Thomas","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0325","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1089\/scd.2014.0269","article-title":"No evidence for circulating mesenchymal stem cells in patients with organ injury","volume":"23","author":"Hoogduijn","year":"2014","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.molmed.2018.12.006_bib0330","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/jor.21167","article-title":"Circulating plastic adherent mesenchymal stem cells in aged hip fracture patients","volume":"28","author":"Alm","year":"2010","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.molmed.2018.12.006_bib0335","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/stem.1198","article-title":"Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms","volume":"30","author":"Teo","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.molmed.2018.12.006_bib0340","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev.med.47.1.315","article-title":"Role of endothelium in thrombosis and hemostasis","volume":"47","author":"Wu","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0345","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI23284","article-title":"Endothelial cell culture: beginnings of modern vascular biology","volume":"114","author":"Nachman","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2018.12.006_bib0350","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2012-03-420612","article-title":"Mesenchymal stem cells are injured by complement after their contact with serum","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2018.12.006_bib0355","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","article-title":"Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications","volume":"113","author":"Steffel","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2018.12.006_bib0360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","article-title":"Complement and coagulation: strangers or partners in crime?","volume":"28","author":"Markiewski","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0365","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0370","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0375","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","article-title":"Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis","volume":"3","author":"Hashmi","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0380","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2213-2600(15)00047-8","article-title":"Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome","volume":"3","author":"Ringden","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0385","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Multi Scler. Relat. Disord."},{"key":"10.1016\/j.molmed.2018.12.006_bib0390","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/MIB.0000000000000441","article-title":"Human placenta-derived cells (PDA-001) for the treatment of moderate-to-severe Crohn\u2019s disease: a Phase 1b\/2a study","volume":"21","author":"Melmed","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.molmed.2018.12.006_bib0395","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3389\/fimmu.2017.00795","article-title":"Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis","volume":"8","author":"Baygan","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0400","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","article-title":"Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study","volume":"9","author":"Liang","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.molmed.2018.12.006_bib0405","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1089\/scd.2015.0329","article-title":"Effects of freeze-thawing and intravenous infusion on mesenchymal stromal cell gene expression","volume":"25","author":"Hoogduijn","year":"2016","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.molmed.2018.12.006_bib0410","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.2337\/db13-0896","article-title":"Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity","volume":"62","author":"Acosta","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2018.12.006_bib0415","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/sctm.17-0031","article-title":"Concise review: a safety assessment of adipose-derived cell therapy in clinical trials: a systematic review of reported adverse events","volume":"6","author":"Toyserkani","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0420","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.ymthe.2018.08.011","article-title":"PDGF restores the defective phenotype of adipose-derived mesenchymal stromal cells from diabetic patients","volume":"26","author":"Capilla-Gonzalez","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2018.12.006_bib0425","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.5966\/sctm.2015-0272","article-title":"Type 1 diabetes mellitus donor mesenchymal stromal cells exhibit comparable potency to healthy controls in vitro","volume":"5","author":"Davies","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.molmed.2018.12.006_bib0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085040","article-title":"Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?","volume":"9","author":"Moll","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2018.12.006_bib0435","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/14653240903401840","article-title":"Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice","volume":"12","author":"Deak","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.molmed.2018.12.006_bib0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/scrt198","article-title":"Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies","volume":"4","author":"Quimby","year":"2013","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.molmed.2018.12.006_bib0445","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/096368916X692609","article-title":"Control of IBMIR induced by fresh and cryopreserved hepatocytes by low molecular weight dextran sulfate versus heparin","volume":"26","author":"Gustafson","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.molmed.2018.12.006_bib0450","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13287-018-0936-8","article-title":"Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine","volume":"9","author":"Netsch","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.molmed.2018.12.006_bib0455","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/voxs.12133","article-title":"Engineering more efficient multipotent mesenchymal stromal (stem) cells for systemic delivery as cellular therapy","volume":"10","author":"Moll","year":"2015","journal-title":"ISBT Sci. Ser."},{"key":"10.1016\/j.molmed.2018.12.006_bib0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-45457-3_7","article-title":"Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy?","volume":"951","author":"Moll","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0465","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000485735","article-title":"Placenta-derived decidua stromal cells for hemorrhagic cystitis after stem cell transplantation","volume":"139","author":"Aronsson-Kurttila","year":"2018","journal-title":"Acta Haematol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0470","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrgastro.2013.204","article-title":"Liver support strategies: cutting-edge technologies","volume":"11","author":"Struecker","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2018.12.006_bib0475","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ekir.2018.05.009","article-title":"Extracorporeal stromal cell therapy for subjects with dialysis-dependent acute kidney injury","volume":"3","author":"Miller","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.molmed.2018.12.006_bib0480","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.biomaterials.2015.02.110","article-title":"Biomaterials based strategies for skeletal muscle tissue engineering: existing technologies and future trends","volume":"53","author":"Qazi","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2018.12.006_bib0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060461","article-title":"Mesenchymal stem cells engineered to inhibit complement-mediated damage","volume":"8","author":"Soland","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2018.12.006_bib0490","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.biomaterials.2016.05.055","article-title":"Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage","volume":"102","author":"Li","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2018.12.006_bib0495","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/mt.2016.142","article-title":"Local inhibition of complement improves mesenchymal stem cell viability and function after administration","volume":"24","author":"Li","year":"2016","journal-title":"Mol. Ther."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491418302405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491418302405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:17:55Z","timestamp":1761463075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491418302405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1471491418302405"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2018.12.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravascular Mesenchymal Stromal\/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}